

Principales sources et références

UNION DES NUTRITHÉRAPEUTES FRANCOPHONES

Qu'est-ce que le cancer ?

Mécanismes de développement d'un cancer

1. Béliveau R. Cuisiner les aliments contre le cancer. *Ldp Bien Etre*, 2010.
2. Cancer Prevention Overview (PDQ®). Patient Version. PDQ Screening and Prevention Editorial Board, Published March 8, 2019: https://www.ncbi.nlm.nih.gov/books/NBK65987/ Consulté pour la dernière fois en février 2020
3. Chapter 3: Mechanisms of carcinogenesis – IARC - International Agency for Research on Cancer (OMS). Mechanisms of Carcinogenesis - IARC Publications Consulté pour la dernière fois en février 2020
4. James E Talmadge et al. AACR Centennial Series : The Biology of Cancer Metastasis: Historical Perspective. *Cancer Res*, 2010, 70 (14): 5649–5669
5. Tracey A et al. Cancer Invasion and Metastasis : Molecular and Cellular Perspective, in Metastatic Cancer: Clinical and Biological Perspectives edited by Rahul Jandial - Madame Curie Bioscience Database, www.ncbi.nlm.nih.gov/books/NBK164700/

P53

6. Chakraborty A et al. Guarding the 'translation apparatus': Defective ribosome biogenesis and the p53 signaling pathway. *Wiley interdisciplinary reviews*, 2011, RNA. 2. 507-22
7. Hafner A et al. The multiple mechanisms that regulate p53 activity and cell fate. *Nature Reviews – Molecular Cell Biology*, 2019, volume 20
8. Haronikova L et al. The p53 mRNA: an integral part of the cellular stress Response. *Nucleic Acids Research*, 2019, Vol. 47, No. 7 3257–3271
9. Li Y et al. Functional Diversity of p53 in Human and Wild Animals. *Frontiers in Endocrinology*, 2019, 10:152.

Réparation de l'ADN

10. Astley SB et al. Evidence that dietary supplementation with carotenoids and carotenoid-rich foods modulates the DNA damage: repair balance in human lymphocytes. *Br J Nutr*, 2004, 91
11. Berger NA, Sikorski GW. Nicotinamide stimulates repair of DNA damage in human lymphocytes. *Biochem Biophys Res Commun*, 1980, 95 (1) : 67-72
12. Chambon P et al. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. *Biochem Biophys Res Commun*, 1963, 11 : 39–43
13. Chen L et al. Nicotinamide adenine dinucleotide based therapeutics. *Curr Med Chem*, 2008, 15 (7) : 650-70
14. Collins AR et al. Effects of micronutrients on DNA repair. *Eur J Nutr*, 2012, 51 (3) : 261-79
15. Collins, AR et al. Nutritional modulation of DNA repair in a human intervention study. *Carcinogenesis*, 2003, 24, 511-515.
16. Houtkooper RH et al. The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways. *Endocr Rev*, 2010, 31 (2) : 194–223
17. Kirkland JB. Niacin requirements for genomic stability. *Mutat Res*, 2011 Nov 28
18. Masutani M et al. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease. *Cell Mol Life Sci*, 2005,62 (7-8) : 769-83
19. Ramos AA et al. Antigenotoxic effects of quercetin, rutin and ursolic acid on HepG2 cells : evaluation by the comet assay. *Toxicol Lett*, 2008, 177, 66-73
20. Ramos AA et al. Polyphenolic compounds from Salvia species protect cellular DNA from oxidation and stimulate DNA repair in cultured human cells. *J Agric Food Chem*, 2010, 58, 7465-7471
21. Ramos AA et al. Protective effects of ursolic acid and luteolin against oxidative DNA damage include enhancement of DNA repair in Caco-2 cells. *Mutat Res*, 2010, 692, 6-11
22. Weitberg AB. Effect of nicotinic acid supplementation in vivo on oxygen radical-induced genetic damage in human lymphocytes. *Mutat Res*, 1989, 216 (4) : 197-201

Traitements des cancers

23. Fondation contre le cancer : https://www.cancer.be/le-cancer/traitements-du-cancer?gclid=EAIaIQobChMIlpWMvrf_4AIVz4CfCh09Ygm2EAAYASAAEgI_YPD_BwE Consulté pour la dernière fois en février 2020
24. Kaufman HL et al. The promise of Immuno-oncology: implications for defining the value of cancer treatment. *J Immunother Cancer*, 2019; 7: 129.
25. Li Y and Sun R. Tumor immunotherapy: New aspects of natural killer cells. *Chin J Cancer Res*, 2018 Apr;30(2):173-196

Quels sont les facteurs déclencheurs et aggravants des cancers ?

Habitudes alimentaires, toxiques et cancers

26. https://www.cancer.gov/about-cancer/causes-prevention/risk Consulté pour la dernière fois en février 2020
27. Ames BN et al. Are vitamin and mineral deficiencies a major cancer risk? *National Review cancer*, 2002 Sep 2(9):694-704
28. Anand P et al. Cancer is a preventable disease that requires major lifestyle changes. *Pharmaceutical Research* 2008, Sept 25(9)2097-116
29. De Almeida CV et al. Role of diet and gut microbiota on colorectal cancer. Immunomodulation. *World J Gastroenterol*, 2019 January 14; 25(2): 151-162.
30. Fiolet T et al. Consumption of ultra-processed foods and cancer risk : results from NutriNet-Santé prospective cohort. *BMJ*, 2018 ; 360 :k322
31. Hogervorst JG et al. A prospective study of dietary acrylamide intake and the risk of endometrial, ovarian, and breast cancer. *Cancer Epidemiol Biomarkers Prev*, 2007, 16 (11) : 2304-13
32. Koutros S et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. *Cancer Res*, 2009, 1 ; 69 (5) : 1877-84
33. Lee HW et al. Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. *Oncotarget*, 2014, 5 (11) : 3526–3540
34. Maisonneuve P et al. Risk factors for pancreatic cancer : a summary review of meta-analytical studies. *Int J Epidemiol*, 2014 Dec 14
35. Menke A et al. Cadmium Levels in Urine and Mortality among U.S. Adults. *Environ Health Perspect*, 2009, 117 (2) : 190–196
36. Moutapam D. Cancer du sein : comment le prévenir par la nutrition, *Editions Beaudelaire*
37. Niedzwiecki A et al. Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. *Cancer Metastasis Rev.,* 2010 Sep ; 29(3) :529-42
38. Pariza M. Mutagens and carcinogens in the diet, Wiley-Liss, New York, 1990 Sugimura T, Carcinogenicity of mutagenic heterocyclic amines formed in the cooking process. *Mutation Research*, 1985, 150, 33-41
39. Pelucchi C et al. Exposure to acrylamide and human cancer - a review and meta-analysis of epidemiologic studies. *Ann Oncol*, 2011, 22 (7) : 1487-99
40. Pelucchi C et al. Dietary acrylamide and cancer risk : an updated meta-analysis. *Int J Cancer*, 2014 Nov 18
41. Stott-Miller M et al. Consumption of deep-fried foods and risk of prostate cancer. *Prostate*, 2013, 73 (9): 960–969.
42. Tsai HJ, Chang JS. Environmental Risk Factors of Pancreatic Cancer. *J Clin Med*. 2019 Sep 10;8(9). pii: E1427
43. Willet W.C. Diet and Cancer. *Oncologist,* 2000, 5:393-404
44. Zheng W et al. Well-done Meat Intake, Heterocyclic Amine Exposure, and Cancer Risk. *Nutr Cancer*, 2009, 61 (4) : 437–446
45. https://fr.wikipedia.org/wiki/Acrylamide ou https://www.efsa.europa.eu/fr/topics/topic/acrylamide ou https://www.anses.fr/fr/content/l%E2%80%99acrylamide-dans-les-aliments

Stress oxydant et cancers

46. Anetor JI. Industrialization and the increasing risk of genome instability in developing countries: nutrigenomics as a promising antidote. *Afr J Med Med Sci*, 2010; 39 Suppl : 7-20
47. Bitorina AV et al . Low profile high value target: The role of OxLDL in cancer. *Biochim Biophys Acta Mol Cell Biol Lipids*, 2019 Aug 31:158518
48. Chen C et al. Effects of Chronic and Acute Ozone Exposure on Lipid Peroxidation and Antioxidant Capacity in Healthy Young Adults. *Environ Health Perspect*, 2007, 115(12): 1732–1737
49. Di Domenico M et al. The Role of Oxidative Stress and Hormones in Controlling Obesity. *Front Endocrinol (Lausanne)*, 2019 Aug 13;10:540
50. Dossus L et al. Active and passive cigarette smoking and breast cancer risk: Results from the EPIC cohort. *Int J Cancer*, 2014, 134 (8):1871-88
51. Khurana VG et al. Cell phones and brain tumors: a review including the long-term epidemiologic data. *Surg Neurol*, 2009, 72 (3) 205-14
52. Konstantin Salnikow et al. Genetic and Epigenetic Mechanisms in Metal Carcinogenesis and Cocarcinogenesis : Nickel, Arsenic and Chromium. *Chem Res Toxicol*, 2008, 21 (1) : 28–44
53. Ma E et al. Dietary antioxydant micronutrients and all-cause mortality : the Japan collaborative cohort study for evaluation of cancer risk. *J Epidemiol*, 2018 May 2
54. Mohr SB et al. Are low ultraviolet B and high animal protein intake associated with risk of renal cancer? *Int J Cancer*, 2006 Dec 1; 119(11): 2705–2709.
55. Rapports ANSES Radiofréquences et Santé, 2013 - www.anses.fr/fr/documents/AP2011sa0150Ra.pdf
56. Ristow M et al. Oxidative metabolism in cancer growth. *Curr Opin Clin Nutr Metab Care*, 2006, 9 (4) : 339-45
57. Sakanyan V. Reactive Chemicals and Electrophilic Stress in Cancer: A Minireview. *High Throughput*, 2018 Apr 27;7(2)
58. Valavanidis A et al. 8-hydroxy-2’-deoxyguanosine (8-OHdG) : a critical biomarker of oxidative stress and carcinogenesis. *J Environ Sci Health C Environ Carcino Ecotoxicol Rev*, 2009, 27(2):120-39
59. Winter M et al. Prevalence of risk factors for breast cancer in German airline cabin crew: a cross-sectional study. *J Occup Med Toxicol*, 2014, 9:27

Inflammation et cancers

60. da Cruz BO et al. Nutritional strategies to modulate inflammation pathways via regulation of peroxisome proliferator-activated receptor β/δ. *Nutr Rev*, 2019 Oct 4. pii: nuz058
61. Fowler ME et al. Meta-analysis of the association between dietary inflammatory index (DII) and cancer outcomes. *Int J Cancer*., 2017, 141 (11): 2215-2227
62. Grant WB et al. An ecological study of cancer mortality rates including indices for dietary iron and zinc. *Anticancer Res*, 2008, 28 (3B): 1955-63
63. Hayashi T et al. Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer. *Cancers* (Basel). 2019 Aug 12;11(8). pii: E1153
64. Jang H et al. Association between the Dietary Inflammatory Index and Risk for Cancer Recurrence and Mortality among Patients with Breast Cancer. *Nutrients*, 2018, 10 (8): 1095
65. Kaluza J et al. Influence of anti-inflammatory diet and smoking on mortality and survival in men and women : two prospective cohort studies. *J Intern Med*, 12 septembre 2018
66. Lowndess SA et al. The role of copper in tumour angiogenesis. *J Mammary Gland Biol Neoplasia*, 2005, 10, 4 : 299–310
67. Qian BZ. Inflammation fires up cancer metastasis. *Semin Cancer Biol*, 2017 Aug 31, pii: S1044-579X(17) 30210-9
68. Phillips CM et al. Dietary Inflammatory Index and Non-Communicable Disease Risk: A Narrative Review. *Nutrients*, 2019 Aug 12;11(8). pii: E1873
69. Shinko D et a. Cancer-related systemic inflammation: The challenges and therapeutic opportunities for personalized medicine. *Clin Pharmacol Ther*, 2017 Oct; 102(4) :599-610
70. Shivappa N et al. Designing and developing a literature-derived, population-based dietary inflammatory index. *Public Health Nutr*, 2014, 17 (8) : 1689-96
71. Singh N et al. Inflammation and cancer. *Ann Afr Med*, 2019 Jul-Sep;18(3):121-126
72. Torti SV et al. Iron and cancer: more ore to be mined. *Nat Rev Cancer*, 2013, 13 (5) : 342–355.
73. Triantafillidis JK et al. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. *Anticancer Res*, 2009, 29 (7) : 2727-37
74. Zamora-Ros R et al. Dietary inflammatory index and inflammatory gene interactions in relation to colorectal cancer risk in the Bellvitge colorectal cancer case-control study. *Genes Nutr*, 2015 ; 10(1) : 44
75. Zitvogel L et al. Nutrition, inflammation and cancer. *Nat Immunol.,* 2017 Jul 19; 18 (8):843-850
76. Zucchetto Antonella et al. Dietary inflammatory index and prostate cancer survival. *Int J Cancer*., 2016, 139(11) : 2398–2404

Hormone de croissance et cancers

77. Boguszewski CL and Boguszewski MCDS. Growth Hormone's Links to Cancer. *Endocr Rev*, 2019 Apr 1;40(2):558-574
78. Chesnokova V et al. Excess growth hormone suppresses DNA damage repair in epithelial cells. *JCI Insight*, 2019 Feb 7;4(3). pii: 125762
79. Lu M et al. Targeting growth hormone function: strategies and therapeutic applications. *Signal Transduct Target Ther*, 2019 Feb 8;4:3
80. Perry JK et al. Growth hormone and cancer : an update on progress. *Curr Opin Endocrinol Diabetes Obes*, 2013, 20 (4) : 307-13

Surpoids, Obésité et cancers

81. Agurs-Collins T et al. The Many Faces of Obesity and Its Influence on Breast Cancer Risk. *Front Oncol*, 2019 Sep 4;9:765
82. Frasca D et al. Adipose Tissue: A Tertiary Lymphoid Organ: Does It Change with Age? *Gerontology*, 2019 Aug 14:1-8
83. Gaillard RC. Le tissu adipeux : un véritable organe endocrine. *Rev Med Suisse,* 2003; volume -1.22822
84. Goralski KB et al. More Than an Adipokine: The Complex Roles of Chemerin Signaling in Cancer. *Int J Mol Sci*, 2019 Sep 26;20(19). pii: E4778
85. Hu H et al. Visceral adipose tissue and the risk of colorectal adenomas : a meta-analysis of observational studies. *Eur J Cancer Prev*, 2014 Dec 9
86. Jacobs EJ et al. The Association of Body Mass Index with Pancreatic Cancer: Variation by Age at Body Mass Index Assessment. *Am J Epidemio*, 2019 Oct 11. pii: kwz230
87. Laurent V et al. Tissu adipeux et cancer, Une association à haut risque. *Med Sci (Paris)*. 2014 April; 30(4): 398–404
88. Liu R and Nikolajczyk BS. Tissue Immune Cells Fuel Obesity-Associated Inflammation in Adipose Tissue and Beyond. *Front Immunol*, 2019 Jul 17;10:1587
89. Naik A et al. The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer. *Front Immunol*, 2019 Aug 14;10:1940
90. Picon-Ruiz M et al. Obesity and adverse breast cancer risk and outcome : Mechanistic insights and strategies for intervention. *CA Cancer J Clin*, 2017 Sept67(5):378-397
91. Sánchez-Jiménez F et al. Obesity and Breast Cancer: Role of Leptin. *Front Oncol*, 2019 Jul 18;9:596
92. Wagner M et al. Adipose tissue macrophages : the inflammatory link between obesity and cancer ? *Expert Opin Ther Targets*, 2014 Dec 4 : 1-12
93. Yehuda-Shnaidman E et al. Secreted human adipose leptin decreases mitochondrial respiration in HCT116 colon cancer cells. *PLoS One*, 2013 ; 8 (9)
94. Wu X. Cancer-associated adipocytes: key players in breast cancer progression. *J Hematol Oncol*, 2019 Sep 10;12(1):95
95. Zhou B et al. Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms. *Pancreatology*, 2019 Aug 16. pii: S1424-3903(19)30689-1

Viande, produits laitiers et cancers

96. Adebamowo CA et al. High school dietary dairy intake and teenage acne. *J Am Acad Dermatol*, 2005 ; 52 (2) : 207-14
97. Aune D et al. Dairy products, calcium, and prostate cancer risk : a systematic review and meta-analysis of cohort studies. *Am J Clin Nutr*, 2015 Jan ; 101 (1) : 87-117 19
98. Di Maso M et al. Food consumption, meat cooking methods and diet diversity and the risk of bladder cancer. Cancer Epidemiol, 2019 Sep 26;63:101595
99. Ganmaa D et al. The experience of Japan as a clue to the etiology of testicular and prostatic cancers. *Med Hypotheses*, 2003, 60 (5) : 724-30
100. Goldie YL et al. Targeting cancer by binding iron : dissecting cellular signaling pathways. *Oncotarget*, 2015, 6 (22) : 18748–18779
101. Grant WB et al. An ecological study of cancer mortality rates including indices for dietary iron and zinc. *Anticancer Res*, 2008 ; 28 (3B) : 1955-63
102. Hedlund M et al. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. *Proc Natl Acad Sci U S A*, 2008, 105 (48) : 18936-41
103. Hogervorst JG et al. A prospective study of dietary acrylamide intake and the risk of endometrial, ovarian, and breast cancer. *Cancer Epidemiol Biomarkers Prev*, 2007; 16 (11) : 2304-13
104. Hyun-Wook Lee et al. Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. *Oncotarget*, 2001, 4 ; 5 (11) : 3526–3540
105. Kolahdooz F et al. Meat, fish, and ovarian cancer risk : Results from 2 Australian case-control studies, a systematic review, and meta-analysis. *Am J Clin Nutr*, 2010; 91 (6) : 1752-63
106. Koutros S et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. *Cancer Res*, 2009, 1 ; 69 (5) : 1877-84
107. Kroenke CH et al. High- and low-fat dairy intake, recurrence, and mortality after breast cancer diagnosis. *J Natl Cancer Inst*, 2013, 105 (9) : 616-23
108. Kuriki K et al. The increasing incidence of colorectal cancer and the preventive strategy in Japan. *Asian Pacific J Cancer Prev*, 2000, 7, 495-501
109. McCullough ML et al. Association between red and processed meat intake and mortality among colorectal cancer survivors. *J Clin Oncol*, 2013, 31 (22) : 2773–2782
110. Mursu J et al. Dietary supplements and mortality rate in older women : the Iowa Women's Health Study. *Arch Intern Med*, 2011 ; 171 (18) : 1625-33
111. Parada H, Jr. et al. Grilled, barbecued, and smoked meat intake and survival following breast cancer. *J Natl Cancer Inst*, 2017, 109 (6) : djw299
112. Pelucchi C et al. Dietary acrylamide and cancer risk : An updated meta-analysis*. Int J Cancer.* 2015 Jun 15;136(12):2912-22
113. Pelucchi C et al. Exposure to acrylamide and human cancer - a review and meta-analysis of epidemiologic studies. *Ann Oncol*, 2011; 22 (7) : 1487-99
114. Qin LQ et al. Milk consumption and circulating insulin-like growth factor-I level : a systematic literature review. *Int J Food Sci Nutr*, 2009, 60 Suppl 7 : 330-40
115. Stott-Miller M et al. Consumption of deep-fried foods and risk of prostate cancer. *Prostate*, 2013; 73 (9): 960–969.
116. Torti SV et al. Iron and cancer: more ore to be mined. *Nat Rev Cancer*, 2013, 13 (5) : 342–355.
117. Vijayvergia N et al, Lifestyle Factors in Cancer Survivorship : where We Are and Where We Are Headed, *J Pers Med*, 2015, 5 (3) : 243–263
118. Zheng W et al. Well-done meat intake, heterocyclic amine exposure, and cancer risk. *Nutr Cancer*, 2009, 61 (4) : 437–446

Sucres et cancers

119. http://www.medicalnewstoday.com/articles/307428.php
120. http://www.medicalnewstoday.com/articles/308679.php
121. Cancer : une question de vie et de mort cellulaire : http://www.centreducancer.be/fr/show/index/section/9/page/155
122. Levi F et al. Macronutrients and colorectal cancer: a Swiss case-control study. *Ann Oncol*. 2002 Mar; 13(3): 369–373.

Sel et cancers

123. https://www.cancer.be/les-cancers/facteurs-de-risque/pas-trop-de-sel Dernière mise à jour le 23/08/2017
124. https://www.who.int/elena/titles/sodium_cvd_adults/fr/
125. World Cancer Research Fund / American Institute for Cancer Research; Food, Nutrition, Physical Activity and the Prevention of Cancer, a Global Perspective, Washington D.C. AICR, 2007.
126. Baud G et al. Bile Diversion in Roux-en-Y Gastric Bypass Modulates Sodium-Dependent Glucose Intestinal Uptake. *Cell Metabolism*, March 08, 2016, Vol 23, issue 3, p547-553
127. D'Elia L et al. Dietary salt intake and risk of gastric cancer. *Cancer Treat Res*, 2014;159:83-95
128. Ernest M et al. Biology of Human Sodium Glucose Transporters. *Physiol Rev*, 2011, 91: 733–794
129. Ma Y et al. High salt intake: independent risk factor for obesity? *Hypertension*, 2015 Oct;66(4):843-9
130. Shin JY et al. Relationship between salt preference and gastric cancer screening: An analysis of a nationwide survey in Korea. *Cancer Res Treat*, 2016 Jul;48(3):1037-44.
131. Zhou L et al. INTERMAP Research Group. Salt intake and prevalence of overweight/obesity in Japan, China, the United Kingdom, and the United States: the INTERMAP Study. *Am J Clin Nutr*, 2019 May 21.

Acides gras saturés (AGS), Acides gras Trans et cancers

132. Bassett JK et al. Plasma phospholipid fatty acids, dietary fatty acids and prostate cancer risk. *Int J Cancer*, 2013 ; 1 33 (8) : 1882-91
133. Bidoli E et al. Macronutrients, fatty acids, cholesterol and prostate cancer risk. *Ann Oncol*, 2005 Jan; 16(1): 152–157
134. Chajès V et al. Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC Study. *Am J Epidemiol*. 2008, 1;167(11):1312-20
135. Jackson MD et al. Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica. *Cancer Causes Control*, 2012, 23 (1) : 23-33
136. O'Doherty MG et al. Dietary fat and meat intakes and risk of reflux esophagitis, Barrett's esophagus and esophageal adenocarcinoma. *Int J Cancer*, 2011,129 (6) : 1493-502
137. Pelser C et al. Dietary Fat, Fatty Acids and Risk of Prostate Cancer in the NIH-AARP Diet and Health Study. *Cancer Epidemiol Biomarkers Prev*, 2013, 22 (4) : 697–707
138. Schwab U et al. Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. *Food Nutr Res*, 2014; 58: 10
139. Thiébaut AC et al. Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. *J Natl Cancer Inst*, 2009; 101 (14) : 1001-11

Acides gras polyinsaturés (AGPI) Oméga-6 et cancers

140. Adam O et al. Influence of Dietary Linoleic Acid Intake with Different Fat Intakes on Arachidonic Acid Concentrations in Plasma and Platelet Lipids and Eicosanoid Biosynthesis in Female Volunteers. *Ann Nutr Metab*. 2003;47(1):31-6
141. Alfano CM et al. Fatigue, inflammation, and ω-3 and ω-6 fatty acid intake among breast cancer survivors. *Clin Oncol*. 2012 Apr 20;30(12):1280-7
142. Amézaga J et al. Altered Red Blood Cell Membrane Fatty Acid Profile in Cancer Patients. *Nutrients*. 2018 Dec 1;10(12). pii: E1853
143. Bassett JK et al. Plasma phospholipids fatty acids, dietary fatty acids, and breast cancer risk. *Cancer Causes Control*. 2016 Jun;27(6):759-73
144. Bougnoux P et al. Synthèse - Lipides et cancer du sein : de la prévention au traitement. *Médecine Clinique endocrinologie & diabète*, n° 45, Mars-Avril 2010
145. Burns JL et al. Differentiating the biological effects of linoleic acid from arachidonic acid in health and disease. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 2018;135:1–4
146. Burns-Whitmore B et al. Alpha-Linolenic and Linoleic Fatty Acids in the Vegan Diet: Do They Require Dietary Reference Intake/Adequate Intake Special Consideration? Nutrients. 2019;11,2365
147. de Kok TM et al. Analysis of oxidative DNA damage after human dietary supplementation with linoleic acid. *Food Chem Toxicol*. 2003 Mar;41(3):351-8
148. de Lorgeril M, Salen P. Helping women to good health: breast cancer, omega-3/omega-6 lipids, and related lifestyle factors. *BMC Med*. 2014 Mar 27;12:54
149. Diaz-Aragon R et al. Role of phospholipase D in migration and invasion induced by linoleic acid in breast cancer cells. *Mol Cell Biochem*. 2019 Jul;457(1-2):119-132
150. Fritsche KL. Too much linoleic acid promotes inflammation-doesn't it? *Prostaglandins Leukot Essent Fatty Acids*. 2008 Sep-Nov;79(3-5):173-5
151. Guichardant M et al. Biological relevance of double lipoxygenase products of polyunsaturated fatty acids, especially within blood vessels and brain. *Biochimie*. April 2019;159:55-58
152. Hill EM et al. Dietary polyunsaturated fatty acids modulate adipose secretome and is associated with changes in mammary epithelial stem cell self-renewal. *J Nutr Biochem*. 2019 Sep;71:45-53
153. Huerta-Yépez S et al. Role of diets rich in omega-3 and omega-6 in the development of cancer. *Bol Med Hosp Infant Mex*. 2016 Nov - Dec;73(6):446-456
154. Ines JK and Calder PC. Omega-6 fatty acids and inflammation. *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 2018; 132:41–48
155. Khadge S et al. Immune regulation and anti-cancer activity by lipid inflammatory mediators. *Int Immunopharmacol*. 2018 Dec;65:580-592
156. Khadge S et al. Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival. *Clin Exp Metastasis*. 2018 Dec;35(8):797-818
157. Khadge S et al. Long-Chain Omega-3 Polyunsaturated Fatty Acids Modulate Mammary Gland Composition and Inflammation. *J Mammary Gland Biol Neoplasia*. 2018 Jun;23(1-2):43-58
158. Khankari NK et al. Polyunsaturated fatty acid interactions and breast cancer incidence: a population-based case-control study on Long Island, New York. *Ann Epidemiol*. 2015 Dec;25(12):929-35
159. Kiyabu GY et al. Fish, n - 3 polyunsaturated fatty acids and n - 6 polyunsaturated fatty acids intake and breast cancer risk: The Japan Public Health Center-based prospective study. *Int J Cancer*. 2015 Dec 15;137(12):2915-26
160. Lira LG et al. Plasma and erythrocyte omega-3 and omega-6 fatty acids are associated with multiple inflammatory and oxidative stress biomarkers in breast cancer. *Nutrition*. 2019 Feb;58:194-200
161. Loew A et al. A Role for Lipid Mediators in Acute Myeloid Leukemia. *Int J Mol Sci*. 2019 May 16;20(10). pii: E2425
162. Marangoni F et al. Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects. *Atherosclerosis*. 2020;292:90–98

163. Martinez N et al. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. *Clin Transl Oncol*. 2019 Apr;21(4):489-498
164. Nabasi SF et al. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. *Cancer Metastasis Rev*. 2015 Sep;34(3):359-80
165. Nagata M et al. The ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cancer death in a Japanese community: The Hisayama Study. *Journal of Epidemiology*. 2017;27:578e583
166. Naughton SS et al. Linoleic acid and the pathogenesis of obesity. *Prostaglandins & other Lipid Mediators*. 2016;125:90–99
167. Nindrea RD et al. Association of Dietary Intake Ratio of n-3/n-6 Polyunsaturated Fatty Acids with Breast Cancer Risk in Western and Asian Countries: A Meta-Analysis. *Asian Pac J Cancer Prev*. 2019 May 25;20(5):1321-1327
168. Nindrea RD et al. Protective Effect of Omega-3 Fatty Acids in Fish Consumption Against Breast Cancer in Asian Patients: A Meta-Analysis. *Asian Pac J Cancer Prev*. 2019 Feb 26;20(2):327-332
169. Peppone LJ et al. Multicenter Randomized Controlled Trial of Omega-3 Fatty Acids Versus Omega-6 Fatty Acids for the Control of Cancer-Related Fatigue Among Breast Cancer Survivors. *JNCI Cancer Spectr*. 2019 Jun;3(2):pkz005
170. Rett BS, Whelan J. Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: a systematic review. *Nutr Metab (Lond).* 2011 Jun 10;8:36
171. Silva JR et al. Wound Healing and Omega-6 Fatty Acids: From Inflammation to Repair. *Mediators Inflamm*. 2018 Apr 12;2018:2503950
172. Yang B et al. Ratio of n-3/n-6 PUFAs and risk of breast cancer: a meta-analysis of 274135 adult females from 11 independent prospective studies. *BMC Cancer*. 2014 Feb 18;14:105
173. Yarla NS et al. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. *Semin Cancer Biol*. 2016 Oct;40-41:48-81
174. Zanoaga O et al. Implications of dietary ω-3 and ω-6 polyunsaturated fatty acids in breast cancer. *Exp Ther Med*. 2018 Feb; 15(2): 1167–1176

Quelles sont les pistes de solutions ? Zoom sur l'alimentation et nutriments

Végétaux et cancers

175. Aleksandrova K et al. Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study. *BMC Med*, 2014, 12 (1) : 168
176. Allen NE et al. Macronutrient intake and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. *Int J Cancer*, 2013 Feb 1; 132 (3) : 635-44
177. Béliveau R. La méthode anti-cancer, comment réduire les risques. *Flammarion*, 2014.
178. Epplein M et al. Fruit and Vegetable Consumption and Risk of Distal Gastric Cancer in the Shanghai Women's and Men's Health Studies. *Am J Epidemiol*, 15, 2010, 172(4) : 397–406
179. Hastert TA et al. Adherence to WCRF/AICR cancer prevention recommendations and risk of postmenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev*, 2013, 22 (9) : 1498-508
180. Johansson G et al. Dietary influence on some proposed risk factors for colon cancer: fecal and urinary mutagenic activity and the activity of some intestinal bacterial enzymes. *Cancer Detect Prev*,1997, 21 (3) : 258-66
181. Key TJ et al. Cancer in British vegetarians: updated analyses of 4998 incident cancers in a cohort of 32,491 meat eaters, 8612 fish eaters, 18,298 vegetarians, and 2246 vegans. *Am J Clin Nutr*, 2014 ; 100 (Supplement 1) : 378S-385S
182. Le LT et al. Beyond Meatless, the Health Effects of Vegan Diets: Findings from the Adventist Cohorts. *Nutrients*, Jun 2014 ; 6 (6) : 2131–2147
183. Reglero C, Reglero G. Precision Nutrition and Cancer Relapse Prevention: A Systematic Literature Review. *Nutrients*. 2019 Nov 16;11(11). pii: E2799
184. Servan-Schreiber D. Anticancer : Prévenir et lutter grâce à nos défenses naturelles. *Robert Laffont*, 2007
185. Siegel EM et al. Dietary consumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia. *Gynecol Oncol*, 2010 ; 118 (3) : 289-94
186. Sreedhar A. Next-Gen Therapeutics for Skin Cancer: Nutraceuticals. *Nutr Cancer*. 2018 Jul;70(5):697-709
187. Wang X et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. *BMJ*, 2014 ; 349 : g4490

Crucifères et cancers

188. Aggarwal BB et al. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. *Cell Cycle*, 2005, 4 (9) : 1201-15
189. Ampofo E et al. Targeting the microcirculation by indole-3-carbinol and its main derivate 3,3,'-diindolylmethane : effects on angiogenesis, thrombosis and inflammation. *Mini Rev Med Chem*. 2018, 18 (11) : 962-968
190. Barrera LN et al. Epigenetic and antioxidant effects of dietary isothiocyanates and selenium : potential implications for cancer chemoprevention. *Proc Nutr Soc*, 2012, 71 (2) : 237-45
191. Bradlow HL et al. 2-hydroxy-oestrone : the 'good' estrogen. *J.Endocrinol*.,1996. 150 suppl S259-65
192. Chen DZ et al. Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. *J Nutr, 2001*, 131 : 3294-302.
193. Chinni SR et al. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. *Clin Cancer Res*, 2002, 8 : 1228-36.

194. Choi HS et al. Indole-3-carbinol induces apoptosis through p53 and activation of caspase-8 pathway in lung cancer A549 cells. *Food Chem Toxicol.* 2010, 48(3) : 883-90.
195. Cover CM et al. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. *J Biol Chem*, 1998; 273 : 3838-47.
196. Cover CM et al. Indole-3-carbinol and Tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. *Cancer Res*, 1999, 59 :1244-51.
197. Hong C et al. Bcl-2 family-mediated apoptotic effects of 3,3'-diindolylmethane (DIM) in human breast cancer cells. *Biochem Pharmacol*, 2002, 63 (6) : 1085-97.
198. Hwang C et al. Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. *Am J Transl Res.,* 2016, 8 (1) : 166–176
199. Keshandehghan A et al. Co-Treatment with Sulforaphane and Nano-Metformin Molecules Accelerates Apoptosis in HER2+ Breast Cancer Cells by Inhibiting Key Molecules. *Nutr Cancer*. 2019 Sep 2:1-14
200. Liu X et al. Cruciferous vegetables intake is inversely associated with risk of breast cancer: a meta-analysis. *Breast*, 2013, 22 (3) : 309-13
201. Nachshon-Kedmi M et al. Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells. *Food Chem Toxicol*, 2003, 41 (6) : 745-52.
202. Navarro SL et al. Mechanisms of action of isothiocyanates in cancer chemoprevention : an update. *Food Funct*, 2011, 2 (10) : 579-87
203. Singh-Gupta V et al. B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer. *Cancer Lett.,* 2012, 318 (1) : 86–92
204. Tang L et al. Cruciferous vegetable intake is inversely associated with lung cancer risk among smokers : a case-control study. *BMC Cancer*, 2010, 10: 162
205. Tang L et al. Consumption of raw cruciferous vegetables is inversely associated with bladder cancer risk. *Cancer Epidemiol Biomarkers Prev*, 2008, 17 (4) : 938-44
206. Taylor-Harding B et al. Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. *Br J Cancer*, 2012, 106 (2) : 333–343
207. Wu QJ et al. Cruciferous vegetable consumption and gastric cancer risk : a meta-analysis of epidemiological studies. *Cancer Sci*, 2013, 104 (8) : 1067-73
208. Wu QJ et al. Cruciferous vegetables intake and the risk of colorectal cancer : a meta-analysis of observational studies. *Ann Oncol,* 2013, 24 (4) : 1079–1087

Alliacées et cancers

209. Asemani Y et al. Allium vegetables for possible future of cancer treatment. Phytother Res, 2019 Aug 29
210. Djuric Z et al. Association of Dietary Quercetin with Reduced Risk of Proximal Colon Cancer. *Nutr Cancer*, 2012; 64(3): 351–360.
211. Galeone C et al. Onion and garlic use and human cancer. *Am J Clin Nutr*, 2006, 84 (5) : 1027-32
212. Gao CM et al. Protective effect of allium vegetables against both esophageal and stomach cancer : a simultaneous case-referent study of a high-epidemic area in Jiangsu Province, China. *Jpn J Cancer Res*, 1999; 90 (6) : 614-21
213. Huang J et al. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway. *Mol Nutr Food Res*., 2015, 59 (6) :1063-75
214. Ishikawa H et al. Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. *J Nutr, 2006*, 136 (3 Suppl) : 816S-820S
215. Lai KC et al. Diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in colo 205 human colon cancer cells in vitro and in vivo. *Phytomedicine*, 2012,19 (7) : 625-30
216. Miroddi M et al. Potential beneficial effects of garlic in oncohematology. *Mini Rev Med Chem*, 2011, 11 (6) : 461-72
217. Morales-González JA et al. Garlic (Allium sativum L.): A Brief Review of Its Antigenotoxic Effects. *Foods*, 2019 Aug 13;8(8). pii: E343
218. Nicastro HL et al. Garlic and onions : their cancer prevention properties. *Cancer Prev Res (Phila)*, 2015 Jan 13
219. Peyman M et al. Therapeutic Uses and Pharmacological Properties of Garlic, Shallot, and Their Biologically Active Compounds. *Iran J Basic Med Sci*, 2013, 16 (10) : 1031–1048
220. Setiawan VW et al. Allium Vegetables and Stomach Cancer Risk in China. *Asian Pac J Cancer Prev*, 2005 ; 6 (3) : 387–395
221. Su B et al. Diallyl disulfide inhibits TGF β1 induced upregulation of Rac1 and β catenin in epithelial mesenchymal transition and tumor growth of gastric cancer. *Oncol Rep*., 2018, 39 (6) : 2797-2806
222. Tsubura A et al. Anticancer effects of garlic and garlic-derived compounds for breast cancer control. *Anticancer Agents Med Chem*, 2011, 11(3) : 249-53
223. Wang X et al. Aged black garlic extract induces inhibition of gastric cancer cell growth in vitro and in vivo. *Mol Med Rep*, 2012, 5 (1) : 66-72

Algues, champignons et cancers

224. Alonso EN et al. Genes Related to Suppression of Malignant Phenotype Induced by Maitake D-Fraction in Breast Cancer Cells. *J Med Food*, 2013, 16 (7) : 602–617
225. Ayeka PA et al. Potential of Mushroom Compounds as Immunomodulators in Cancer Immunotherapy : a review. *Evid Based Complement, Alternat Med*., 2018, 2018 : 7271509
226. Cheng S et al. Ganoderma lucidum for cancer treatment : we are close but still not there. *Integr Cancer Ther*, 2015, 14 (3) : 249-57

227. Deng G et al. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients : immunological effects. *J Cancer Res Clin Oncol*, 2009, 135 (9) : 1215-1221
228. Elbatrawy EN et al. Medicinal Mushroom Extracts Possess Differential Antioxidant Activity and Cytotoxicity to Cancer Cells. *Int J Med Mushrooms*, 2015,17 (5) : 471-9
229. Fitton JH et al. Therapies from Fucoidan : an update. *Mar Drugs*, 2015, 13 (9) : 5920–5946
230. Funahash H et al. Seaweed prevents breast cancer ? Jpn. *J. Cancer Res*, 2001, 92 (5) : 483 - 487.
231. Jin X et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. *Cochrane Database Syst Rev*, 2012, (6) : CD007731
232. Kladar NV et al. Ganoderma : insights into anticancer effects. *Eur J Cancer Prev*, 2015 Aug 27
233. Kodama N et al. Can maitake MD-fraction aid cancer patients ? *Altern Med Rev*, 2002, 7 (3) : 236-9
234. Kwak JY et al. Fucoidan as a Marine Anticancer Agent in Preclinical Development. *Mar Drugs*, 2014, 12 (2) : 851–870
235. Lindequist U et al. The Pharmacological Potential of Mushrooms. *Evid Based Complement, Alternat Med*, 2005, 2 (3) : 285–299
236. Liu J et al. Combined Yeast-derived β-Glucan with Anti-tumor Monoclonal Antibody for Cancer Immunotherapy. *Exp Mol Pathol*, 2009, 86 (3) : 208–214
237. Ma HT et al. Anti-diabetic effects of Ganoderma lucidum. *Phytochemistry*, 2015 Jun, 114 : 109-13
238. Martin LJ et al. Fucoxanthin and Its Metabolite Fucoxanthinol in Cancer Prevention and Treatment. *Marine Drugs*, 2015, 13 (8) : 4784–98
239. Moghadamtousi SZ et al. Anticancer and Antitumor Potential of Fucoidan and Fucoxanthin, Two Main Metabolites Isolated from Brown Algae. *Scientific World Journal*, 2014, 2014 : 768323
240. Okam K et al. Adjuvant immunotherapy : two randomized controlled studies of patients with cervical cancer. *Biomedicine Pharmacotherapy*, 1989, 43, 3, 177-181
241. Rokkaku T et al. Anticancer effects of marine carotenoids, fucoxanthin and its deacetylated product, fucoxanthinol, on osteosarcoma. *Int J Oncol*, 2013, 43 (4) : 1176-86
242. Rossi P et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer : an example of complementary and integrative medicine. *Oncotarget*, 2018, 9 (37) : 24837–24856
243. Satomi Y et al. Antitumor and Cancer-preventative Function of Fucoxanthin : a Marine Carotenoid. *Anticancer Research*, 2017, 37 (4) : 1557–1562
244. Suzuki N et al. Efficacy of oral administration of Lentinula eododes mycelia extract for breast cancer patients undergoing postoperative hormone therapy. *Asian Pac J Cancer Prev*, 2013, 14 (6) : 3469-72
245. Taguchi T et al. Life-span prolongation effect of lentinan on patients with advanced or recurrent colorectal cancer. *Int J Immunopharmacol*, 1982, 4 : 271
246. Tanigawa K et al. Improvement of QOL and Immunological Function With Lentinula Edodes Mycelia in Patients Undergoing Cancer Immunotherapy : an Open Pilot Study. *Altern Ther Health Med*, 2016, 22 (4) : 36-42
247. Teas J et al. Dietary seaweed modifies estrogen and phytoestrogen metabolism in healthy postmenopausal women. *J Nutr*, 2009, 139 (5) : 939 - 944
248. Valverde ME et al. Edible Mushrooms : Improving Human Health and Promoting Quality Life. *Int J Microbiol*, 2015, 2015 : 376387
249. Xu T et al. The cancer preventive effects of edible mushrooms. *Anticancer Agents Med Chem*, 2012, 12 (10) : 1255-63
250. Yamaguchi Y et al. Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy : a pilot study. *Am J Chin Med*, 2011, 39 (3) : 451-9
251. Yang YJ. A case-control study on seaweed consumption and the risk of breast cancer. *Br J Nutr*, 2010, 103 (9) : 1345-1353
252. Zhang Y et al. Lentinan as an immunotherapeutic for treating lung cancer : a review of 12 years clinical studies in China. *J Cancer Res Clin Oncol*, 2018 Jul 24
253. Hang S et al. Mushroom consumption and incident risk of prostate cancer in Japan: A pooled analysis of the Miyagi Cohort Study and the Ohsaki Cohort Study. *Int J Cancer*, 2019 Sep 4

Polyphénols et cancers

254. Arora I et al. Combinatorial Epigenetics Impact of Polyphenols and Phytochemicals in Cancer Prevention and Therapy. Int J Mol Sci, 2019 Sep 14;20(18). pii: E4567

Thé, catéchines et cancers

255. Ahn WS et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. *Eur J Cancer Prev*, 2003, 12 (5) : 383-90.
256. Beltz LA et al. Mechanisms of cancer prevention by green and black tea polyphenols. *Anticancer Agents Med Chem.,* 2006, 6 (5) : 389-406
257. Bettuzzi S et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia : a preliminary report from a one-year proof-of-principle study. *Cancer Res*, 2006, 66 (2) : 1234-40
258. Brausi M et al. Chemoprevention of human prostate cancer by green tea catechins : two years later. A follow-up update. *Eur Urol*, 2008, 54 (2) : 472-3
259. Dostal AM et al. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer : results of the Minnesota Green Tea Trial. *Food Chem Toxicol*, 2015 Sept, 83 : 26-35
260. Fujiki H et al. Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins and anticancer compounds. *J Cancer Res Clin Oncol*., 2015 Sep ; 14 (9) :1511-22

261. Hayakawa S et al. Anti-cancer effects of green tea by either anti- or pro-oxidative mechanisms. *Asian Pac J Cancer Prev*, 2016 ;17(4) :1649-54
262. Henning S et al. Chemopreventive Effects of Tea in Prostate Cancer: Green Tea vs. Black Tea. *Mol Nutr Food Res*, 2011, 55 (6), 905–920
263. Islam RH et al. Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea. *Egyptian Journal of Basic and Applied Sciences*, 2018, 5, 1, 1-23
264. Jianhua C et al. Effect of Tea Polyphenol Compounds on Anticancer Drugs in Terms of anti-tumor activity, toxicology and pharmacokinetics. *Nutrients*, 2016 Dec, 8 (12) : 762
265. Khan N et al. Multitargeted therapy of cancer by green tea polyphenols. *Cancer Lett*, 2008 Oct 8, 269 (2) : 269-280
266. Khan N et al. Cancer and metastasis : prevention and treatment by green tea, *Cancer Metastasis Rev*, 2010, 29, 435-445
267. Li Y et al. Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. *Mol Cancer*, 2010, 9, 274
268. McLarty J et al. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. *Cancer Prev Res (Phila)*, 2009, 2 (7) : 673-82
269. Meeran SM et al. Bioactive Dietary Supplements Reactivate ER Expression in ER-Negative Breast Cancer Cells by Active Chromatin Modifications. *PLoS One*, 2012, 7 (5) : e37748
270. Nakachi K et al. Influence of drinking green tea on breast cancer malignancy among Japanese patients. *Jpn J Cancer Res*, 1998, 89 (3) : 254-61
271. Rashidi B et al. Green tea and its anti-anfiogenesis effects. *Biomed Pharmacother*, 2017 May ; 89 ; 949-956
272. Rathore K et al. Green tea catechin extract in intervention of chronic breast cell carcinogenesis induced by environmental carcinogens. *Mol Carcinog*, 2012, 51 (3) : 280-9
273. Sartippour MR et al. The combination of green tea and tamoxifen is effective against breast cancer. *Carcinogenesis*, 2006 , 27 (12) : 2424-33
274. Singh BN et al. Green tea catechin, epigallocatechin-3-gallate (EGCG) : mechanisms, perspectives and clinical applications. *Biochem Pharmacol*, 2011 ; 82 (12) : 1807-21
275. Sinha S et al. Epigenetic reactivation of p21CIP1/WAF1 and KLOTHO by a combination of bioactive dietary supplements is partially ERα-dependent in ERα-negative human breast cancer cells. *Mol Cell Endocrinol*, 2015 May, 406, 102-14
276. Suganuma M et al. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. *Cancer Sci*, 2011, 102 (2) : 317-23
277. Thomas R et al. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer – the UK NCRN Pomi-T study. *Prostate Cancer Prostatic Dis*, 2014 Jun, 17 (2) : 180–186
278. Zou C et al. Green tea compound in chemoprevention of cervical cancer. *Int J Gynecol Cancer,* 2010, 20 (4) : 617-24.

Curcuma, Curcumine et cancers

279. https://www.cancer.be/complementsalimentaires/curcuma consulté octobre 2019
280. http://cam-cancer.org/en/curcumin consulté octobre 2019
281. Adiwidjaja J et al. Curcumin as a clinically-promising anti-cancer agent : pharmacokinetics and drug interactions. *Expert Opin Drug Metab Toxicol*, 2017 Sep ; 13(9) :953-972
282. Agrawal DK et al. Curcumin and its analogues : potential anticancer agents. *Med Res Rev*, 2010, 30 (5) : 818-60
283. Alemi A et al. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy. *J Nanobiotechnology*, 2018, 16 (1) : 28
284. Allegra A et al. Anticancer activity of curcumin and its analogues : Preclinical and clinical studies. *Cancer Invest*, 2017 Jan 2 ; 35(1) :1-22
285. Amin AR et al. Evasion of anti-growth signaling : a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. *Semin Cancer Biol*, 2015, pii : S1044-579X (15) 00013-9
286. Bandyopadhyay D. Farmer to pharmacist : curcumin as an anti-invasive and antimetastatic agent for the treatment of cancer. *Front Chem*, 2014, 2 : 113
287. Bayet-Robert M et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. *Cancer Biol Ther*, 2010, 9 (1) : 8-14
288. Bigelsen S et al. Evidence-based complementary treatment of pancreatic cancer : a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin. *Cancer Manag Res*, 2018, 10 : 2003–2018
289. Bordoloi D et al. Multi-Targeted agents in cancer cell chemosensitization : what we learnt from curcumin thus far. *Recent Pat Anticancer Drug Discov*, 2015 Oct 19
290. Carroll RE et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. *Cancer Prev Res (Phila)*, 2011; 4 (3) : 354-64
291. Cruz-Correa M et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. *Clin Gastroenterol Hepatol*, 2006, 4 (8) : 1035-8
292. Danilenko M et al. Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs. *Exp Cell Res*, 2004, 298 (2) : 339-58
293. Deng YI et al. Molecular mechanisms of anti-metastatic activity of curcumin. *Anticancer Res*, 2016 Nov ; 36(11) :5639-5647
294. Dhillon N et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res*, 2008, 14 (14) : 4491-9
295. Erices JI et al. Current natural therapies in the treatment against glioblastoma. *Phytother Res*, 2018 Aug 15

296. Gupta SC et al, Therapeutic roles of curcumin : lessons learned from clinical trials. *AAPS J*, 2013 Jan ; 15(1) : 195-218
297. Ide H et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. *Prostate*, 2010 ; 70 (10) : 1127-33
298. Jiang M et al. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. *Molecules*, 2013, 18 (1) : 701-20
299. Kanai M et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. *Cancer Chemother Pharmacol*, 2011, 68 (1) : 157-64
300. Kumar P et al. Curcumin as an adjuvant to breast cancer treatment. *Anticancer Agents Med Chem*, 2015,15 (5) : 647-56
301. Kumar B et al. A Novel Curcumin Analog (H-4073) Enhances the Therapeutic Efficacy of Cisplatin Treatment in Head and Neck Cancer. *PLoS One,* 2014; 9(3): e93208.
302. Kunnumakkara AB et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. *Int J Cancer*, 2009 Nov 1;125(9):2187-97
303. Kunnumakkara AB et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. *Cancer Res*, 2007 Apr 15;67(8):3853-61
304. Murray-Stewart T et al. Curcumin mediates polyamine metabolism and sensitizes gastrointestinal cancer cells to antitumor polyamine-targeted therapies. *PLoS One*, 2018, 13 (8) : e0202677
305. Palange AL et al. Modulating the vascular behavior of metastatic breast cancer cells by curcumin treatment. *Front Oncol*, 2012, 2, 161
306. Panahi Y. et al. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. *Phytother Res*, 2014 Oct;28(10):1461-7
307. Rajah TT et al. Genistein in the presence of 17beta-estradiol inhibits proliferation of Erbeta breast cancer cells. *Pharmacology*, 2009 Jun 26 ;84(2) :68-73
308. Rezaee R et al. Curcumin : A potentially powerful tool to reverse cis-pltin-induced toxicity. *Pharmacol Res*, 2017 Mar, 117 :218-227
309. Scarano W et al. Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects : a double act for the treatment of multidrug-resistant cancer. *Biomater Sc*, 2015, 3 (1) : 163-74
310. Schaffer M et al. An update on Curcuma as a functional food in the control of cancer and inflammation. *Curr Opin Clin Nutr Metab Care*, 2015 Nov ; 18(6) :605-11
311. Shakeri A et al. Curcumin : a naturally occurring autophagy modulator. *J Cell Physiol*, 2018 Sep 21
312. Tuorkey MJ et al. Curcumin a potent cancer preventive agent : Mechanisms of cancer cell killing. *Interv Med Appl Sci*, 2014 Dec ; 6 (4) : 139-46
313. Terlikowska K et al. Curcumin in chemoprevention of breast cancer. *Postepy Hig Med Dosw*, 2014; 68: 571–578.
314. Wilken R et al. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. *Mol Cancer*, 2011, 10 : 12
315. Yallapu MM et al. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. *J Ovarian Res*, 2010, 3 : 11
316. Zhang P et al. Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice. *J Exp Clin Cancer Res*, 2017, 36 (1) : 190

Polyphénols de grenade et cancers

317. Adhami VM et al. Cancer chemoprevention by pomegranate : laboratory and clinical evidence. *Nutr Cancer*, 2009, 61 (6) : 811-5
318. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.) : a review. *Altern Med Rev*, 2008, 13 :128-44
319. Kim ND et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. *Breast Cancer Research and Treatment*, 2002, 71 : 203–217
320. Lansky EP et al. Punica granatum (pomegranate) and its potential or prevention and treatment of inflammation and cancer. *J Ethnopharmacol*, 2007, 109, 2 ; 177–206
321. Malik A et al. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. *Proceedings of the National Academy of Sciences, USA*, 2005; 102 : 14813–14818
322. Panth N et al. Anticancer Activity of Punica granatum (Pomegranate) : a Review. *Phytother Res*. 2017, 31 (4) : 568-578
323. Pantuck AJ et al. Phase II Study of Pomegranate Juice forMen with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer. *Clin Cancer Res*. 2006, 12, 13 : 4018–4026
324. Sharma P et al. Pomegranate for Prevention and Treatment of Cancer : an update. *Molecules*, 2017, 22 (1) : E177.
325. Turrini E et al. Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy. *Oxid Med Cell Longev*, 2015, 2015 : 938475
326. Wang L et al. Pomegranate and its components as alternative treatment for prostate cancer. *Int J Mol Sci,* 2014, 15 (9): 14949-66
327. Wang N et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. *Breast Cancer Res Treat*, 2012, 134 (3) : 943–955

Resvératrol et cancers

328. Brizuela et al. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. *FASEB J*, 3 juin 2010
329. Chakraborty S et al. Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha. *BMC Struct Biol*, 2013, 13 : 27
330. da Costa DCF et al. Resveratrol prevents p53 aggregation in vitro and in breast cancer cells. *Oncotarget.* 2018, 9 (49) : 29112–29122.
331. Greving JP et al. Alcoholic beverages and risk of renal cell cancer. *Br J Cancer*, 2007, 97 (3) : 429-33
332. Grønbaek M et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. *Ann Intern Med*, 2000; 133 (6) : 411-9
333. Kim CW et al. Anti-metastatic potential of resveratrol and its metabolites by the inhibition of epithelial-mesenchymal transition, migration, and invasion of malignant cancer cells. *Phytomedicine*. 2016, 5, 23 (14) :1787-1796
334. Kundu JK et al. Cancer chemopreventive and therapeutic potential of resverarol : mechanistic perspectives. *Cancer Lett.* 2008, 269 (2) : 243-61
335. Pelucchi C et al. Alcohol consumption and renal cell cancer risk in two Italian case-control studies. *Ann Oncol*, 2008, 19 (5) : 1003-8
336. Renaud SC et al. Wine, beer, and mortality in middle-aged men from eastern France. *Arch Intern Med*, 1999 ; 159 (16) : 1865-70
337. Yang Y et al. Differential sensitivities of bladder cancer cell lines to resveratol are unrelated to its metabolic profile. *Oncotarget*, 2017, 8 (25) : 40289–40304.

Caroténoïdes et cancers

338. Etminan M et al. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. *Cancer Epidemiol Biomarkers Prev*, 2004 ; 13 (3): 340-5
339. Gann PH et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. *Cancer Res*, 1999; 59(6):1225–1230
340. Giovannucci E et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst*, 1995; 87(23):1767–1776
341. Han H et al. Lycopene Inhibits Activation of Epidermal Growth Factor Receptor and Expression of Cyclooxygenase-2 in Gastric Cancer Cells. *Nutrients*, 2019 Sep 5;11(9)
342. Haseen F et al. Is there a benefit from lycopene supplementation in men with prostate cancer ? A systematic review. *Prostate Cancer Prostatic Dis*., 2009, 12 (4) : 325-32
343. Hughes DA. Effects of carotenoids on human immune function. *Proceedings of the Nutrition Society*, 1999, 58, 713–718
344. Kirsh VA et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev*, 2006; 15(1):92–98
345. Kucuk O et al. Effects of lycopene supplementation in patients with localized prostate cancer. *Exp Biol Med (Maywood)*, 2002, 227 (10) : 881-5
346. Marti R et al. Tomato as a source of carotenoids and polyphenols targeted to cancer prevention. *Cancers (Basel)*, 2016 Jun 20, 8 (6)
347. Paur I et al. Tomato-based randomized controlled trial in prostate cancer patients. Effect on PSA. *Clin Nutr*, 2016, S0261-5614 (16) 30147-9
348. Schwarz S et al. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. *J Nutr*, 2008 ; 138 (1) : 49-53
349. Soares NCP et al. Lycopene Extracts from Different Tomato-Based Food Products Induce Apoptosis in Cultured Human Primary Prostate Cancer Cells and Regulate TP53, Bax and Bcl-2 Transcript Expression. *Asian Pac J Cancer Prev*., 2017, 18 (2) : 339–345.
350. van Breemen R et al. Multitargeted therapy of cancer by lycopene. *Cancer Lett*, 2008, 269 (2) : 339–351.
351. Zhang X et al. Lycopene can reduce prostate-specific antigen velocity in a phase II clinical study in Chinese population. *Chin Med J (Engl)*, 2014, 127 (11) : 2143-6
352. Zu K et al. Dietary lycopene, angiogenesis, and prostate cancer : a prospective study in the prostate-specific antigen era. *J Natl Cancer Inst*, 2014;106 (2) : djt430

Oméga 3 et cancers

353. Abdi J et al. Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells. *J Nutr Biochem*, 2014 Dec, 25 (12) : 1254-62
354. Abe K et al. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. *Anticancer Res.,* 2018, 38 (4) : 2369-2375
355. Albino AP et al. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. *Cancer Res*, 2000, 60 (15) : 4139-45
356. Bagga D et al. Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer. *Nutr Cancer*, 2002, 42:180
357. Baker E. Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Progress in Lipid Research, 2016 ; 64 : 30–56
358. Berquin IM et al. Multi-targeted therapy of cancer by omega-3 fatty acids. *Cancer Lett.,* 2008 Oct 8 ; 269 (2) : 363-377

359. Bougnoux P et al. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid : a phase II trial. *Br J Cancer*, 2009, 101 (12) : 1978–1985
360. Brasky MT et al. Specialty Supplements and Breast Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort. *Cancer Epidemiol Biomarkers Prev*, 2010, 19 (7) : 1696–1708.
361. Calder PC et al. Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition. *Ageing Res Rev*. 2017 Nov;40:95-119
362. Chajès V et al. Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC study. *Am J Epidemiol,* 2008 Apr 4
363. Cockbain AJ et al. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. *Gut*, 2014 Nov, 63 (11) : 1760-8
364. de Lorgeril M et al. Helping women to good health : breast cancer, omega-3/omega-6 lipids, and related lifestyle factors. *BMC Med*, 2014, 12 : 54
365. Epstein MM et al. Dietary fatty acid intake and prostate cancer survival in Örebro County, Sweden. *Am J Epidemiol,* 2012, 176 (3) : 240-5
366. Friedrichs W et al. Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. *Nutr Cancer*, 2011, 63 (5) : 771-7
367. Golkhalkhali B et al. Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients : a randomized controlled trial. *Asia Pac J Clin Oncol*, 2018, 14 (3) : 179-191
368. Goodstine SL et al. Dietary (n-3)/(n-6) fatty acid ratio: possible relationship to premenopausal but not postmenopausal breast cancer risk in U.S. women. *J Nutr*, 2003, 133:1409
369. Greupner T et al. Effects of a 12-week high-α-linolenic acid intervention on EPA and DHA concentrations in red blood cells and plasma oxylipin pattern in subjects with a low EPA and DHA status. *Food Funct*., 2018, 9, 1587
370. Hajjaji N and Bougnoux P. Selective sensitization of tumors to chemotherapy by marine-derived lipids : a review. *Cancer Treat Rev*, 2013, 39 (5) : 473-88
371. Hardman WE. (n-3) fatty acids and cancer therapy. *J Nutr*, 2004 ; 134 (12 Suppl) : 3427S-3430S
372. Harvey KA et al. Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines. *J Neurosurg*, 2015 Mar,122 (3) : 547-56
373. Hsu HC et al. N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes - involvement of uncoupling protein UCP2. *J Biomed Sci*, 2014 Nov, 21 : 101
374. Jeongseon K et al. Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk : a case-control study. *BMC Cancer*, 2009, 9 : 216
375. Joffre C et al. N-3 Polyunsaturated Fatty Acids and the Resolution of Neuroinflammation. *Frontiers in Pharmacology*, September 2019; Volume 10 | Article 1022
376. Kolahdooz F et al. Meat, fish, and ovarian cancer risk : Results from 2 Australian case-control studies, a systematic review, and meta-analysis. *Am J Clin Nutr*, 2010, 91 (6) : 1752-63
377. Lagarde M et al. Structure-function relationships of non-cyclic dioxygenase products from polyunsaturated fatty acids: poxytrins as a class of bioactive derivatives. *Biochimie*, Dec 2014; 107(Pt A): 91–94
378. Manda K et al. Omega-3 fatty acid supplementation i cancer therapy : does eicosapentanoic acid influence the radiosensitivity of tumor cells ? *Strahlenther Onkol*., 2011 Feb ; 187(2) :127-34
379. Maillard V et al. N-3 and N-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France. *Int J Cancer*, 2002, 98:78
380. Miyata H et al. Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. *Nutrition*, 2017, 33 : 204-210
381. Murphy RA et al. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. *Cancer,* 2011,117 (16) : 3774-80
382. Nakamura K et al. Influence of preoperative administration of omega-3 fatty acid-enriched supplement on inflammatory and immune responses in patients undergoing major surgery for cancer. *Nutrition*, 2005, 21 (6) : 639-49
383. Pala V et al. Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. *J Natl Cancer Inst*, 2001, 18;93(14):1088-95
384. Pardini RS et al. Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents. *Chem Biol Interact*, 2006, 162 (2) :89-105
385. Pastore CA et al. Introduction of an omega-3 enriched oral supplementation for cancer patients close to the first chemotherapy : may it be a factor for poor compliance ? *Nutr Cancer*, 2014, 66 (8) : 1285-92
386. Patterson R et al. Marine Fatty Acid Intake Is Associated with Breast Cancer Prognosis. *J Nutr.,* 2011, 141 (2) : 201–206
387. Piazzi G et al. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. *Int J Cancer*, 2014, 135 (9) : 2004-13
388. Pouchieu C et al. Prospective Associations between Plasma Saturated, Monounsaturated and Polyunsaturated Fatty Acids and Overall and Breast Cancer Risk – Modulation by Antioxidants : A Nested Case-Control Study. *PLoS One*. 2014; 9(2): e90442
389. Sawada N et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. *Gastroenterology*, 2012 ; 142 (7) : 1468-75
390. Shannon J et al. Erythrocyte fatty acids and breast cancer risk : a case-control study in Shangaï, China. *Am J Clin Nutr*. 2007 Apr ;85(4) :1090-7
391. Siddiqui RA et al. Docosahexaenoic acid : a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects. *Biofactors*, 2011 Nov-Dec ; 37(6) :399-412

392. Simonsen et al. Adipose tissue omega-3 and omega-6 fatty acid content and breast cancer in the EURAMIC study. European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer. *Am J Epidemiology*, 1998, 147:342
393. Szymanski KM et al. Fish consumption and prostate cancer risk : a review and meta-analysis. *Am J Clin Nutr*, 2010, 92 (5) : 1223-33
394. Takezaki T et al. Diet and lung cancer risk from a 14-year population-based prospective study in Japan : with special reference to fish consumption. *Nutr Cancer*, 2003, 45 (2) : 160-7
395. Thiébaut AC et al. Dietary intakes of omega-6 and omega-3 polyunsaturated fatty acids and the risk of breast cancer. Int J Cancer, 2009, 124 (4) : 924-31
396. Vasudevan A et al. Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer. *Cancer Prev Res (Phila)*, 2014 Sept 5.
397. Villani AM et al. Fish oil administration in older adults : is there potential for adverse events ? A systematic review of the literature. *BMC Geriatr*, 2013, 13 : 41
398. Yee LD et al. ω-3 Fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition. *Am J Clin Nutr*, 2010, 91 (5) : 1185–1194
399. Watson JE et al. Emerging class of omega-3 fatty acid endocannabinoids & their derivatives. *Prostaglandins Other Lipid Mediat*. 2019 Aug;143:106337
400. Wu Z et al. Omega-3 fatty acid improves the clinical outcome of hepatectomized patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma. *J Biomed Res*, 2012, 26 (6) : 395–399

Huile d'olive et cancers

401. Fortes C et al. Evaluation of the anti-angiogenic potential of hydroxytyrosol and tyrosol, two bio-active phenolic compounds of extra virgin olive oil, in endothelial cell cultures. *Food Chem*, 2012, 134 : 134–140
402. Hernáez Á, Estruch R. The Mediterranean Diet and Cancer: What Do Human and Molecular Studies Have to Say about It? *Nutrients*. 2019 Sep 9;11(9). pii: E2155
403. Psaltopoulou T et al. Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of 13800 patients and 23340 controls in 19 observational studies. *Lipids Health Dis*, 2011 ; 10: 127

Fibres et cancers

404. https://www.lanutrition.fr/les-news/contre-le-cancer-du-sein-faites-le-plein-de-fibres
405. Barnard RJ et al. Effects of a low-fat, high-fiber diet and exercise program on breast cancer risk factors in vivo and tumor cell growth and apoptosis in vitro. *Nutr Cancer,* 2006;55:28–34
406. Breneman CB and Tucker L. Dietary fibre consumption and insulin resistance—the role of body fat and physical activity. *Br J Nutr*, 2013;110(2):375–383
407. Farvid MS et al. Dietary Fiber Intake in Young Adults and Breast Cancer Risk. *Pediatrics*, 2016 Mar;137(3):1-11.
408. Gerber M. Fiber and breast cancer: another piece of the puzzle—but still an incomplete picture. *J Natl Cancer Inst*, 1996;88(13):857–858
409. Jia-Yi D et al. Dietary fiber intake and risk of breast cancer: a meta-analysis of prospective cohort studies. *Am J Clin Nutr*, first published July 20, 2011.
410. Ma Y et al. Single-component versus multicomponent dietary goals for the metabolic syndrome: a randomized trial. *Ann Intern Med*, 2015 Feb 17;162(4):248-57.
411. Maino Vieytes CA et al. Dietary Fiber, Whole Grains, and Head and Neck Cancer Prognosis: Findings from a Prospective Cohort Study. *Nutrients*, 2019 Sep 27;11(10). pii: E2304
412. Oh H. Different dietary fibre sources and risks of colorectal cancer and adenoma: a dose-response meta-analysis of prospective studies. *Br J Nutr*, 2019 Jul 2:1-11
413. Rose DP et al. High-fiber diet reduces serum estrogen concentrations in premenopausal women. *Am J Clin Nutr*, 1991;54(3):520–525
414. Carbohydrate intake, glycemic index and prostate cancer risk. AUA annual meeting. Communication du 20 mai 2014 10h30. Résumé PD31-11. *Prostate Cancer: Epidemiology & Natural History*.

Lignanes, lin et cancers

415. Aberg UW et al. Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo. *PLoS ONE*, 2011, 6 (9)
416. Brooks JD et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. *Am J Clin Nutr*, 2004, 79 (2) : 318-325
417. Buck K et al. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. *Am J Clin Nutr*, 2010, 92 (1) : 141 - 153
418. Buck K et al. Serum enterolactone and prognosis of postmenopausal breast cancer. *J Clin Oncol*, 2011, 29 (28): 3730 - 3738
419. Guglielmini P et al. Serum enterolactone levels and mortality outcome in women with early breast cancer : a retrospective cohort study. *Breast Cancer Res Treat*, 2012, 132 (2) : 661 - 668
420. Haggans CJ et al. The effect of flaxseed and wheat bran consumption on urinary estrogen metabolites in premenopausal women. *Cancer Epidemiol Biomarkers Prev*, 2000, 9 (7) : 719-725
421. McCann SE et al. Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. *Breast Cancer Res Treat*, 2010,122 (1) : 229-35

422. Thompson LU et al. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. *Clin. Cancer Res*, 2005, 11 (10) : 3828 – 3835

Phytoestrogènes de soja et cancers

423. Caan BJ et al. Soy food consumption and breast cancer prognosis. *Cancer Epidemiol Biomarkers Prev,* 2011 May ;20(5) :854-8
424. Fritz H et al. Soy, Red Clover, and Isoflavones and Breast Cancer : A Systematic Review. *PLoS One*, 2013, 8 (11) : e81968
425. Guha N et al. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors : the Life After Cancer Epidemiology study. *Breast Cancer Res Treat*, 2009,118 (2) : 395-405
426. Horakova D et al. Risks and protective factors for triple negative breast cancer with a focus on micronutrients and infections. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, 2018 May 15
427. Ide H et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. *Prostate*, 2010, 70 (10) : 1127-33
428. Kang X et al. Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. *CMAJ*, 2010, 182 (17) : 1857–1862
429. Kweon SS et al. Intake of specific nonfermented soy foods may be inversely associated with risk of distal gastric cancer in a Chinese population. *J Nutr*, 2013 ;143 (11) : 1736-42
430. Lee SA et al. Adolescent and adult soy food intake and breast cancer risk : results from the Shanghai Women's Health Study. *Am J Clin Nutr*, 2009 ; 89 (6) : 1920-6
431. Li Y et al. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. *Mol Cancer*, 2013, 12, 9
432. Li Y et al. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. *Cancer Res*, 2005, 65 (15) : 6934-42
433. Mahmoud AM et al. Soy isoflavones and prostate cancer : a review of molecular mechanisms. *J Steroid Biochem Mol Biol*, 2014; 140 : 116-32
434. Nagaraju GP et al. Pleiotropic effects of genistein in metabolic, inflammatory and malignant diseases. *Nutr Rev*, 2013 Aug ; 71(8) :562-72
435. Nagata C et al. Factors to consider in the association between soy isoflavone intake and Breast Cancer risk. *J Epidemiol*, 2010, 20 (2): 83–89
436. Park SY et al. Legume and isoflavone intake and prostate cancer risk: The Multiethnic Cohort Study. *Int J Cancer*, 2008; 123(4): 927–932.
437. Pudenz M et al. Impact of soy isoflavones on the epigenome in cancer prevention. *Nutrients*, 2014; 6 (10) : 4218-72
438. Sarkar FH et al. Soy isoflavones and cancer prevention. *Cancer Invest*, 2003; 21 (5) : 744-57
439. Shu XO et al. Soy food intake and breast cancer survival. *JAMA*, 2009, 302 (22) : 2437-43.
440. Vaishampayan U et al. Lycopene and soy isoflavones in the treatment of prostate cancer. *Nutr Cancer*, 2007, 59 (1)
441. Wu AH et al. Epidemiology of soy exposures and breast cancer risk. *Br J Cancer,* 2008 Jan 15 ;98(1) :9-14

Nutriments et cancers

442. Ames BN. Prevention of mutation, cancer and other age-associated diseases by optimizing micronutrient intake. *J Nucleic Acids*, 2010 Sep 22:2010, 725071
443. Mokbel K et al. Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies. *Anticancer Res*, 2019 Oct;39(10):5231-5259

Vitamine C et cancers

444. Carr AC et al. Intravenous Vitamin C for Cancer Therapy – Identifying the Current Gaps in Our Knowledge. *Front Physiol*, 2018, 9 : 1182
445. Carr AC et al. Relief from cancer chemotherapy side effects with pharmacologic vitamin C. *N Z Med J*, 2014, 127 (1388) : 66-70
446. Du J et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. *Clin Cancer Res*, 2010, 16 (2) : 509–520.
447. Fritz H et al. Intravenous Vitamin C and Cancer : a Systematic Review. *Integr Cancer Ther*, 2014, 13 (4) : 280-300
448. Harris HR et al. Vitamin C and survival among women with breast cancer : a meta-analysis. *Eur J Cancer*, 2014 May, 50 (7) : 1223-31
449. Harris HR et al. Vitamin C intake and breast cancer mortality in a cohort of Swedish women. *Br J Cancer*, 2013, 109 (1) : 257-64
450. Holm LE et al. Treatment failure and dietary habits in women with breast cancer. *J Natl Cancer Inst*, 85 : 32-36, 1993
451. Ingram D. Diet and subsequent survival in women with breast cancer. *Br J Cancer*, 69 : 592-595, 1994
452. Jain M et al. Premorbid diet and the prognosis of women with breast cancer. *J Natl Cancer Inst*, 86:13901397, 1994
453. Jenab M et al. Plasma and dietary vitamin C levels and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *Carcinogenesis*, 2006 ; 27(11) : 2250-7
454. Mikirova N et al. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. *J Transl Med*, 2012, 10 : 189
455. Mikirova N et al. Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. *Journal of Translational Medicine*, 2013, 11 : 191
456. Moertel CG et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. *N Engl J Med*, 1985, 312 (3) : 137-41
457. Monti DA et al. Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. *PLoS One*. 2012, 7 (1) : e29794
458. Rohan TE et al. Dietary factors and survival from breast cancer. *Nutr Cancer*, 20 :167-177, 1993

Magnésium et cancers

459. Dai Q et al. The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. *Am J Clin Nutr*, 2007, 86 (3) : 743–751.
460. Dai Q et al. Blood Magnesium and the Interaction with Calcium on the Risk of High-Grade Prostate Cancer. *PLoS One*, 2011, 6 (4): e18237
461. Deng X et al. Magnesium, vitamin D status and mortality : results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. *BMC Med*, 2013, 11 : 187
462. Mahabir S et al. Dietary magnesium and DNA repair capacity as risk factors for lung cancer. *Carcinogenesis*, 2008, 29 (5) : 949–956

Zinc et cancers

463. Epstein MM et al. Dietary zinc and prostate cancer survival in a Swedish cohort. *Am J Clin Nutr*, 2011; 93 (3) : 586-93
464. Ho E et al. Zinc deficiency, DNA damage and cancer risk. *Nutr Biochem*, 2004, 15 (10) : 572-8
465. Kolenko V et al. Zinc and zinc transporters in prostate carcinogenesis. *Nat Rev Urol*, 2013, 10(4) : 219–226.
466. Zhang X et al. A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. *Cancer Causes Control*, 2011 ; 22 (12) : 1627–1637

Folates et cancers

467. Chiang FF et al. High serum folate might have a potential dual effect on risk of colorectal cancer. *Clin Nutr*, 2014 Nov 8
468. Lee JE et al. Folate intake and risk of colorectal cancer and adenoma: modification by time. Am J Clin Nutr, 2011 Apr;93(4):817-25
469. Liu Y et al. Vitamin and multiple-vitamin supplement intake and incidence of colorectal cancer: a meta-analysis of cohort studies. *Med Oncol*, 2015 Jan; 32 (1) : 434
470. Piyathilake CJ et al. Folate and vitamin B12 may play a critical role in lowering the HPV 16 methylation-associated risk of developing higher grades of CIN. *Cancer Prev Res (Phila),* 2014, 7 (11) : 1128-37
471. Zhang YF et al. Folate intake and the risk of breast cancer : a dose-response meta-analysis of prospective studies. *PLoS One*, 2014, 9 (6) : e100044
472. Tio M et al. Folate intake and the risk of prostate cancer : a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*, 2014, 17(3) : 213-9
473. Wien TN et al. Cancer risk with folic acid supplements : a systematic review and meta-analysis. *BMJ Open*, 2012; 2 (1) : e000653

Vitamine D et cancers

474. Bhatia V et al. Restoration of the anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D by silibinin in vitamin D-resistant colon cancer cells. *Cancer Lett*, 2015 Apr, Pii : S0304-3835 (15) 00244-X
475. Bjelakovic G et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev, 2014 Jan 10;(1):CD007470
476. Blutt SE, Weigel NL. Vitamin D and prostate cancer. *Proc Soc Exp Biol Med*, 1999, 221 (2) : 89–98
477. Brosseau C et al. Role of Insulin-Like Growth Factor Binding Protein-3 in 1, 25-Dihydroxyvitamin-D3-Induced Breast Cancer Cell Apoptosis. *Int J Cell Biol*, 2013, 2013 : 960378
478. Danilenko M et al. Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs. *Exp Cell Res*., 2004, 298 (2) : 339-58.
479. Deeb KK et al. Vitamin D signalling pathways in cancer : potential for anticancer therapeutics. *Nat Rev Cancer*, 2007 Sep, 7(9) :684-700
480. Feskanich D et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev*, 2004 ; 13 (9) : 1502–1508
481. Garland CF et al. Vitamin D and prevention of breast cancer : pooled analysis. *J Steroid Biochem Mol Biol*, 2007 ; 103 (3–5) : 708–711
482. Garland CF et al. The Role of Vitamin D in Cancer Prevention. *Am J Public Health*, 2006, 96 (2) : 252–261Grant WB et al, Ecological studies of the UVB-vitamin D-cancer hypothesis, Anticancer Res, 2012, 32 (1) : 223-36
483. Gewirtz DA et al. Vitamin D3 and vitamin D3 analogues as an adjunct to cancer chemo-therapy and radiotherapy. *Curr Med Chem Anticancer Agents*, 2002, 2 (6) : 683-90
484. Karthikayan A et al. Low serum 25-hydroxy vitamin D levels are associated with aggressive breast cancer variants and poor pronostic factors in patients with breast carcinoma. *Arch Endocrinol Metab*, 2018 Aug, 62 (4) : 452-459
485. Krishnan AV et al. Vitamin D and breast cancer : inhibition of estrogen synthesis and signaling. *J Steroid Biochem Mol Biol*, 2010, 121 (1-2) : 343-8
486. Ma Y et al. Mechanistic insights of vitamin D anticancer effects. *Vitam Horm*, 2016 ; 100 :395-431
487. Ma Y et al. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy. *Cancer Biomark*, 2017 ; 18(3) :297-303
488. Marwan GF et al. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. *Int J Colorectal Dis*, 2009, 24 (2) : 219–224
489. Revuelta IR et al. Systematic review and meta-analysis : prevalence and possible causes of vitamine D deficiency and insufficiency in pediatric cancer patients. *Clin Nut,* 2015 Jan 16

490. Schöttker B et al. Vitamin D and mortality : meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. *BMJ*, 2014, 348
491. Trump DL et al. Vitamin D compounds : clinical development as cancer therapy and prevention agents. *Anticancer Res*., 2006, 26 (4A) : 2551-6
492. Viala M et al. Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer : a retrospective study. *BMC Cancer*, 2018, 18 (1) : 770
493. Wahler J et al. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer. *J Steroid Biochem Mol Biol*, 2015 Apr, 148 : 148-55
494. Wong GL et al. Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B. *Clin Gastroenterol Hepatol,* 2015 Apr, 13 (4) : 783-790. e1
495. Zeichner SB et al. Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. *Clin Breast Cancer*, 2015, 15 (1) : e1-11

Vitamine K2 et cancers

496. Habu D et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. *JAMA*, 2004, 292 (3) : 358-61
497. Juanola-Falgarona M et al. Dietary Intake of Vitamin K Is Inversely Associated with Mortality Risk. *J Nutr*, 2014, May 1, 113, 187740
498. Kakizaki S et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. *J Gastroenterol Hepatol*, 2007, 2 (4) : 518-22
499. Nimptsch K et al. Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). *Am J Clin Nutr*, 2008, 87, (4) : 985–92

Microbiote et cancers

500. Voir 11 De Almeida CV et al. Role of diet and gut microbiota on colorectal cancer. Immunomodulation. *World J Gastroenterol*, 2019 January 14; 25(2): 151-162
501. https://netcancer.net/publications/le-microbiote-intestinal-un-nouvel-acteur-en-oncologie/ Consulté pour la dernière fois en février 2020
502. https://netcancer.net/actualites/effet-du-microbiote-sur-la-reponse-a-limmunotherapie-pr-ghiringhelli/ Consulté pour la dernière fois en octobre 2019.
503. https://www.biocodexmicrobiotainstitute.com/les-microbiotes Consulté pour la dernière fois en février 2020
504. Blander JM et al. Regulation of inflammation by microbiota interactions with host. *Nat Immunol*, 2017 Jul 19 ; 18(8) :851-860
505. Bultman SJ. Emerging roles of the microbiome in cancer. *Carcinogenesis*, 2014 Feb ; 35(2) : 249-55
506. Arkan MC. The intricate connection between diet, microbiota and cancer : A jigsaw puzzle. *Semin Immunol*., 2017 Sep 1, pii : S1044-5323(17)30023-4
507. Bultman SJ. The microbiome and its potential as a cancer preventive intervention. *Semin Oncol*, 2016 Feb ; 43 (1) : 97-106
508. De Almeida CV et al. Role of diet and gut microbiota on colorectal cancer. Immunomodulation. *World J Gastroenterol,* 2019 January 14; 25(2): 151-162.
509. Gopalakrishnan V et al. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. *Cancer cell*, 2018
510. Kostic AD et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor immune microenvironment. *Cell Host Microbe*, 2013.
511. Iida N et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science*, 2013.
512. Liu F et al. Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer. *Int J Biol Sc*, 2019 Sep 7;15(11):2381-2392
513. Matson V et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science*, 2018.
514. Paulos CM et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. *Journal of Clinical Investigation*, 2007.
515. Pedersen et al. The Human Intestinal Microbiome in Health and Disease. *The new england journal of medicine*, 2016.
516. Redman MG et al. The efficacy and safety of probiotics in people with cancer : a systematic review. *Ann Oncol*, 2014 May 11,
517. Routy B et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science*, 2018.
518. Roy S et al. Microbiota : a key orchestrator of cancer therapy. *Nat Rev Cancer*, 2017 May ; 17(5) :271-285
519. Rubinstein MR et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. *Cell Host Microbe*, 2013.
520. Sivan A et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science*, 2015.
521. Sommer F. and Backhed F. The gut microbiota-masters of host development and physiology. *Nature reviews Microbiology*, 2013.
522. Song M et al. Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. *Gastroenterology*, 2019 Oct 3. pii: S0016-5085(19)41369-3
523. Vetizou M et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*, 2015.
524. Viennois E et al. Chronic Inflammatory Diseases: Are We Ready for Microbiota-based Dietary Intervention? *Cell Mol Gastroenterol Hepatol*, 2019;8(1):61-71
525. Vlaud S et al, The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide, Science, 2013

526. Zeller G et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology*, 2014.
527. Wallace BD et al. Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme. *Science*, 2010.

Quelles sont les pistes de solutions ? Zoom sur les bonnes pratiques

Le jeûne dans le traitement des cancers

528. Bauersfeld SP et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer : a randomized cross-over pilot study. *BMC Cancer*, 2018, 18 (1) : 476
529. Brandhorst S et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance and healthspan. *Cell Metab*, 2015, 22 (1) : 86–99
530. Cheng CW et al. Prolonged Fasting reduces IGF-1/PKA to promote hematopoietic stem cell-based regeneration and reverse immunosuppression. *Cell Stem Cell*, 2014, 14 (6) : 810–823.
531. de Groot S et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients : a randomized pilot study. *BMC Cancer*, 2015, 15 : 652
532. Fontana L et al. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. *Aging Cell*, 2008,7 (5) : 681-7
533. Kogevinas M et al. Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study). *Int J Cancer*, 2018 Jul 17
534. Lee C et al. Starvation, detoxification, and multidrug resistance in cancer therapy. *Drug Resist Updat*, 2012, 15 (1-2) : 114–122.
535. Marinac CR et al. Prolonged Nightly Fasting and Breast Cancer Prognosis. *JAMA Oncol*., 2016, 2 (8) : 1049-55
536. Safdie FM et al. Fasting and cancer treatment in humans : a case series report. *Aging (Albany NY)*, 2009, 1 (12) : 988–1007

Sarcopénie et cancers

537. An JM et al. Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia. *J Clin Biochem Nutr*, 2019 Sep;65(2):109-117
538. Barret M et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. *NutrCancer*, 2014 ; 66 (4) : 583-9
539. Gonzalez MC et al. Obesity paradox in cancer : new insights provided by body composition. *Am J Clin Nutr*, 2014 ; 99 (5) : 999-1005
540. Kidd AC et al. Cancer cachexia in thoracic malignancy: a narrative review. *Curr Opin Support Palliat Care*, 2019 Oct 4

Les troubles du sommeil, la mélatonine et cancers

541. Bae SA et al. At the interface of lifestyle, behaviour and circadian rhythms: metabolic implications. Front Nutr. 2019 Aug 28;6:132
542. Blask DE. Melatonin, sleep disturbance and cancer risk. *Sleep Med Rev*, 2009 , 13 : 257–64
543. Caplan LS et al. Breast cancer and electromagnetic fields – a review. *Ann Epidemiol*, 2000; 10 (1) : 31-44
544. Gassmann AS et al. Have female flight attendants an over-risk of breast cancer? *Gynecol Obstet Fertil*, 2014 Oct 31
545. Jia Y et al. Does night work increase the risk of breast cancer ? A systematic review and meta-analysis of epidemiological studies. *Cancer Epidemiol*, 2013; 37 (3) : 197-206
546. Kakizaki M et al. Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. *Br J Cancer*, 2008, 99 : 1502–5.
547. Kolstad HA. Nightshift work and risk of breast cancer and other cancers-a critical review of the epidemiologic evidence. *Scand J Work Environ Health*, 2008, 34 : 5–22.
548. Lissoni P et al. Is there a role for melatonin in supportive care? *Support Care Cancer*, 2002; 10 (2) : 110-6
549. Megdal SP et al. Night work and breast cancer risk : a systematic review and meta-analysis. *Eur J Cancer*, 2005; 41 (13) : 202332
550. Rafnsson V et al. Risk of breast cancer in female flight attendants : a population-based study (Iceland). *Cancer Causes Control*, 2001;12 (2) : 95-101
551. Thompson CL et al. Short duration of sleep increases risk of colorectal adenoma. *Cancer*, 2010, 117 : 841–7
552. Verkasalo PK et al. Sleep duration and breast cancer : a prospective cohort study. *Cancer Res*, 2005, 65 : 9595.
553. Viswanathan AN et al. Night shift work and the risk of endometrial cancer. *Cancer Res*, 2007, 67: 10618
554. Wu AH et al. Sleep duration, melatonin and breast cancer among Chinese women in Singapore. *Carcinogenesis*, 2008, 29 : 1244–8.

Stress et cancers

555. Antonova L et al. Stress and breast cancer : from epidemiology to molecular biology. *Breast Cancer Res*, 2011; 13 (2)
556. Moreno-Smith M et al. Impact of stress on cancer metastasis. *Future Oncol*, 2010; 6 (12) : 1863–1881
557. Pudrovska T et al. Higher-Status Occupations and Breast Cancer : A Life-Course Stress Approach. *Soc Sci Med*, 2013; 89: 53–61
558. Wirth M et al. The Epidemiology of Cancer Among Police Officers. *Am J Ind Med*, 2013; 56 (4) : 439–453

Exercices/Activités physiques et cancers

559. Davies NJ et al. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship : a review of the literature. *Br J Cancer*, 2011, 105 (Suppl 1) : S52–S73
560. Luan X et al. Exercise as a prescription for patients with various diseases. J Sport Health Sci, 2019 Sep;8(5):422-441
561. Pekmezi DW et al. Updated evidence in support of diet and exercise interventions in cancer survivors. *Acta Oncol*, 2011, 50 (2) : 167-78
562. Schmidt T et al. Physical activity influences the immune system of breast cancer patients. *J Cancer Res Ther*, 2017 Jul-Sep ; 13(3) :392-398

Quelques Contre-indications

563. https://www.cancer.be/complementsalimentaires/20475
564. Vogel J. et al. Handboek voeding bij kanker, Utrecht: de Tijdstroom, 2012.
565. https://www.cbip.be/fr/start